stem cell reagents
Effective Use of Resources in Difficult Times
In scientific research, there is a tendency to have everything done in our own lab just so that you can say so, after all, scientific credit is the core criterion researchers are evaluated on. You say wait a minute, don’t we always encourage exchange of materials and COLLABORATION on projects? Sure, but not often enough to make “encouragement” unnecessary. Many “collaborations” are more like sharing of materials with conditions.
In business, collaboration is more in the form of OUTSOURCING or CO-DEVELOPMENT (sometimes through licensing), because doing everything by one’s own employees just doesn’t make much financial sense even for the mega-sized, we-have-everything type of companies. One friend of ours working at a Johnson & Johnson site once told us that a line of research using gene silencing technologies was debated but never moved forward because the lack of confidence in expertise: we are not expert on RNAi, how do we trust our own data? For most biotech and early-stage pharma companies, hiring an expert to do a task brings about too much uncertainty, not to mention cost efficiency.
“Having the expert do it” by outsourcing is somewhat more acceptable to the industry than the academia because the “We are the experts” mentality is more dominant in the latter. Heck, if we don’t believe “We are the experts” in our own field of research, then why do we even do it in the first place? In business though, who is the expert is not something one fights for if the end product or contribution to profit is not made.
The current economic conditions caused many large biotech and pharma companies to lay off thousands upon thousands of employees, in one case of Pfizer layoff, scientist positions were particularly targeted for elimination. Life goes on. Economic downturns are also opportunities for becoming lean and mean, using ways of doing things with much improved efficiency and productivity such as outsourcing, and finding new areas for long term growth.
Categories
- Allele Mail Bag
- cGMP
- Customer Feedback
- Fluorescent proteins
- iPSCs and other stem cells
- nAb: Camelid Antibodies, Nanobodies, VHH
- Next Generation Sequencing (NextGen Seq)
- NIH Budget and You
- oligos and cloning
- Open Forum
- RNAi patent landscape
- SBIR and Business issues
- State of Research
- Synthetic biology
- Uncategorized
- Viruses and cells
- You have the power
Archives
- October 2018
- April 2018
- March 2018
- January 2018
- October 2017
- September 2017
- August 2017
- March 2017
- February 2017
- January 2017
- November 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- October 2015
- September 2015
- August 2015
- June 2015
- March 2015
- January 2015
- December 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- May 2012
- April 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- October 2008
- August 2008
- July 2008